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Abstract
Background: The efficiencies of T cell based immunotherapies are affected by insufficient migration and activation
of tumor specific effector T cells in the tumor. Accumulating evidence exists on the ability of ionizing radiation to
modify the tumor microenvironment and generate inflammation. The aim of this phase I/II clinical trial is to
evaluate whether low dose single fraction radiotherapy can improve T cell associated antitumor immune response
in patients with pancreatic cancer.
Methods/Design: This trial has been designed as an investigator initiated; prospective randomised, 4-armed,
controlled Phase I/II trial. Patients who are candidates for resection of pancreatic cancer will be randomized into 4
arms. A total of 40 patients will be enrolled. The patients receive 0 Gy, 0.5 Gy, 2 Gy or 5 Gy radiation precisely
targeted to their pancreatic carcinoma. Radiation will be delivered by external beam radiotherapy using a 6 MV
Linac with IMRT technique 48 h prior to the surgical resection. The primary objective is the determination of an
active local external beam radiation dose, leading to tumor infiltrating T cells as a surrogate parameter for
antitumor activity. Secondary objectives include local tumor control and recurrence patterns, survival, radiogenic
treatment toxicity and postoperative morbidity and mortality, as well as quality of life. Further, frequencies of tumor
reactive T cells in blood and bone marrow as well as whole blood cell transcriptomics and plasma-proteomics will
be correlated with clinical outcome. An interim analysis will be performed after the enrolment of 20 patients for
safety reasons. The evaluation of the primary endpoint will start four weeks after the last patient’s enrolment.
Discussion: This trial will answer the question whether a low dose radiotherapy localized to the pancreatic tumor
only can increase the number of tumor infiltrating T cells and thus potentially enhance the antitumor immune
response. The study will also investigate the prognostic and predictive value of radiation-induced T cell activity
along with transcriptomic and proteomic data with respect to clinical outcome.
Trial registration: ClinicalTrials.gov - NCT01027221
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Pancreatic cancer is still one of the most lethal cancers
with very unfortunate prognosis. The mortality rate fol-
lows closely the incidence rate. It ranks 9
th in incidence
but 4
th in cancer related death [1], leaving the patients
at first diagnosis with an overall median survival of 6-10
month. So far, surgery is the only chance of cure in this
devastating disease [2]. However, intended curative sur-
gery is possible in about 20% only and even these
patients have a median survival expectancy of less than
two years [3].
Unfortunately, many treatment studies including sur-
gery, chemotherapy and conventional radiotherapy have
shown little progress in improving the prognosis of pan-
creatic cancer patients in the last decades. Therefore,
novel alternatives such as therapies that alter the
immune response are of high interest in this type of
cancer. This is even more the case, since in pancreatic
cancer several ways warding off spontaneously induced
immune responses have been described [4]: The aggres-
sive nature of pancreatic ductal carcinoma is partially
due to its tumor microenvironment with stellate cells
producing the typical excessive desmoplasia [5,6]. It has
been shown in experimental cancer models in nude
mice that tumors grew faster when pancreatic cancer
cells and stellate cells were injected together [7]. Stellate
cells can support growth, invasion, metastasis and che-
moresistance of tumors. Furthermore through recruit-
ment and activation of stroma cell populations,
pancreatic cancers generate a predominantly immune
-suppressive microenvironment [8]
T-cell responses are partially regulated by dendritic
cells, which take up antigens. Dendritic cells present the
antigens to naïve T-cells and thereby activate them.
Cytokines like type 1 interferon and extracellular matrix
degregation products enhance dendritic cell activation,
while IL-10 and TGF-b1 inhibit dendritic cell activation.
In pancreatic cancer IL-10 and TGF-b1 are produced by
stellate cells, cancer infiltrating macrophages and mast
cells or regulatory T-cells [9,10]. IL-10 and TGF-b1c a n
also be upregulated by irradiation e.g. in endothelial
cells [11].
In pancreatic cancer MHC molecules and the Fas-
receptor are downregulated making the cells more resis-
tant to recognition and lysis by activated T-cells. Con-
versely, ionizing radiation has been shown to upregulate
MHC molecules and Fas-receptors in vivo [12].
Gastrointestinal tumours, including pancreatic cancer
induce, attract and maintain regulatory T-cells, which
inhibit effector T-cells activation and function [13,14].
Regulatory T cells and effector T-cells exhibit differ-
ences in their radiosensitivity [15] which opens a dose
window for radiation induced immunotherapy.
Radiotherapy is a substantial part in the multimodal
treatment of many solid cancers. The general under-
standing of the biology of radiation has been dominated
by mitotic-catastrophic or apoptotic cell death. In addi-
tion to the classical effects such as DNA damage radia-
tion also affects most other cell signaling circuits
including MiRNA [16] which affects both the tumor cell
and normal cell compartments with all aspects of the
tumor microenvironment [17]. Although radiation treat-
ment has been known to be immunosuppressive, there
is emerging evidence, that the effectiveness of radiation
therapy can in part be due to its immunostimulating
consequences [18,19].
Potential mechanisms leading to immune response for
ionizing radiation involve activation of stress response
pathways e.g. activation of p53 and NF-B. These abd
others can regulate expression of molecules that pro-
mote a proinflammatory immune response including
TNF-a, Interleukin-1 (IL-1), ICAM-1, VCAM-1, MHC
molecules or PDGF [20]. Stimulation of the NF-Ba n d
the direct cell death resulting from ionizing radiation
also stimulates invasion and activation of leukocytes
leading to a productive immune response [21].
Cytokines can act to inhibit immune responses, e.g.
IL-10 and TGF-b, while others like TNF-a,I F N –a and
IL-1 are proinflammatory [22]. TGF-a and IL-1 have
been found to increase after sublethal total body irradia-
tion, as have TGF-b and IL-6 [23]. The release of these
cytokines leads to recruitment and activation of leuko-
cytes from peripheral blood and extravasation into tissue
and tumors.
Insufficient migration of effector T lymphocytes may
considerably account for the hitherto low clinical effi-
ciency of clinical immunotherapy. Adhesion molecules
such as ICAM-1, E- and particularly P-Selectin are
located on the endothelial cell surface and mediate the
immigration of effector T lymphocytes and other
immune cells into human epithelial tumours [24]. Vas-
cular endothelial cells upregulate ICAM-1 and E-Selec-
tin as a response to ionizing radiation and thereby
facilitate leukocyte arrest and transmigration [25].
Chemokines are chemotactic cytokines that facilitate
directional migration of cells expressing a cognate che-
mokine receptor. Two important chemokines regulated
by ionizing radiation are CXCL-16 and SDF-1 [26].
Mice deficient of CXCR6 (the CXCL-16 responding
receptor) have been demonstrated to exhibit decreased
CD8+ cell recruitment and radiotherapy responsiveness
[27]. It has also been demonstrated, that macrophage
infiltration following RT was dependent on the SDF-1a
expression. Thus ionizing radiation can regulate chemo-
kines either via recruitment of tumor suppressive CD8
cells or tumor promoting cells such as macrophages.
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ductive anti-tumor T-cell response. Antigen-Presenting
cells capture antigens and following processing present
those on their cell surface vial major histocompatability
complexes (MHC). T-cells recognize antigens bound to
MHC and initiate anti-tumor response. Ionizing radia-
tion also upregulates MHC class I on tumor cells and
antigen-presenting cells [28] indicating that ionizing
radiation can enhance tumor cell recognition by T-cells.
Moreover, ionizing radiation can activate endothelial
cells thus facilitating the immigration of T-cells into the
tumor. Overall, the available preclinical in vivo data sup-
port the hypothesis that radiation may provide at least
some of the necessary maturation signals.
To date, no systematic clinical trial on the question if
and how low dose radiotherapy can enhance immune
activity in tumors. One question to address this is to
determine the effective radiation dose to cause immune
response. Furthermore, no data are yet available with
respect to the specific radiosensitivity of the different
cellular components of the immune system, or the
microenvironment, and no data are available describing
effects of radiation on circulating immune cells.
The here presented study describes a clinical phase I/
II trial in pancreatic cancer patients with scheduled
resection. The pancreatic cancer will be irradiated two
days prior to planned surgery using precision external
beam radiotherapy by photon intensity modulated radio-
therapy (IMRT). Primary endpoints are the local radia-
tion dose leading to tumor infiltrating T4 cells as a
surrogate parameter for antitumor activity. Secondary
objectives include clinical parameters such as local
tumor control, patient survival, treatment related toxi-
city as well as quality of life of the patients. Further-
more, frequencies of tumor reactive T cells in blood and
bone marrow will be correlated with blood cell whole
genome transcriptional and plasma-protein analyses.
Methods/Design
Trial Organisation/Coordination
This trial is organised by the joint trial office of the
Departments of Visceral Surgery and Radiation Oncol-
ogy of the University Hospital Center and the Radiation
Oncology Department of the German Cancer Research
Center (dkfz), Heidelberg, Germany. The radiotherapy
will be carried out by the Radiation Oncology at dkfz
and surgery will be performed at the Surgery Depart-
ment of the University Hospital Center Heidelberg.
Translational studies will be carried out by the Depart-
ment of Translational Immunology of dkfz, the Radia-
tion Oncology Departments if dkfz and the Surgery
Departments of the University Hospital. This trial is an
investigator initiated trial and is coordinated by the
Radiation Oncology Department of dkfz and the
Department of Visceral Surgery of the University Hospi-
tal Center Heidelberg. The Radiation Oncology Depart-
ment of dkfz is responsible for the overall trial
management, trial registration, database management,
quality assurance including monitoring and scientific
program of all trial related meetings. (Trial number
NCT01027221)
Ethical and legal considerations
The final clinical trial protocol, the patient information
and informed consent sheets were approved by the inde-
pendent ethics committee of the University of Heidel-
berg S080/2008 (http://klinikum.uni-heidelberg.de).
Further, the study was approved by the German Federal
Authorities for Radiation Protection (Bundesamt fuer
Strahlenschutz, Salzgitter, Trial Number Z5-22461/2-
2009-003) Written informed consent is obtained from
each patient in oral and written form before inclusion in
the study. No data specifically required for this trial will
be obtained if informed consent is not given. Patients
are informed about the strict confidentiality of their per-
sonal data within this trial, but their pseudonymised
medical records may be reviewed for trial purposes by
authorized individuals other than their treating
physician.
Patients will be informed about the additional specific
risk of a bone marrow aspiration, which is voluntarily
and will not lead to exclusion from the study in case of
refusal.
It will be emphasized that the participation is volun-
tary and that the patient is allowed to refuse further par-
ticipation in the protocol whenever he/she wants. This
will not prejudice the patient’s subsequent care. This
study is carried out in accordance to the current
Declaration of Helsinki (sixth revision, 2008), the princi-
ples of “Good Clinical Practice"; (GCP), and the Federal
Data Protection Act. It is registered at the Clinical-
Trials.gov protocol registration system (http://www.clini-
caltrials.gov) and the assigned identification number is
NCT01027221
Study design
This single fraction radiation on operable pancreatic
cancer trial is a registered (ClinicalTrials.gov -
NCT01027221), investigator initiated, prospective, ran-
domized controlled phase I/II trial meant to evaluate
the optimal neoadjuvant, single fraction radiation dose
for patients who will undergo resection for colorectal
liver metastases in curative intent. Patients will be ran-
domised either to the control group -receiving no radia-
tion- or the three treatment groups - receiving 0.5 Gy, 2
Gy or 5 Gy single fraction radiation to the metastasis 48
h prior to the resection of the metastasis. The treatment
is offered to a heterogeneous group of patient of both
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irradiation a highly conformal dose distribution to the
tumor with 2 cm safety margin is delivered using a 6
MV LINAC and IMRT treatment application.
After the inclusion of 20 patients an interims analysis
will be performed. The final analysis will be performed
within three month of the inclusion of the last patient.
T h et r i a ld e s i g nw i l ln o tb ec h a n g e dw i t h o u tp r i o r
agreement of the ethics committee.
Safety aspects and adverse events
Due to the relatively low dose of the applied radiation
dose to the tumor only, there are only very few potential
local adverse events to be expected (AE). Potential AE
include skin alterations e.g. redness, transient nausea,
diarrhea or temporary elevated transaminases, although
these AEs even rarely occur in conventional radiother-
apy using considerably higher doses (e.g. neoadjuvant 5
× 5Gy for rectal or gastric cancer, 54 Gy in pancreatic
cancer). Possible AEs will be scored by the RTOG Scale.
Objective of the study
The primary objectives of this trial are the determina-
tion of the single fraction radiation dose, which leads to
an optimal anti-tumor immune response. The number
of tumor infiltrating T-cells will serve as a surrogate
marker for anti-tumor immune response. Secondary
molecular objectives are the T cell activity in the
resected tumor, the density of regulatory T cells in the
resected tumor, the frequency of tumor reactive T cells
in blood and bone marrow in correlation with changes
in the level of proteins involved in immune response or
angiogenesis and transcriptomics in whole blood cells.
Further clinical secondary objectives are acute radio-
genic toxicity, postoperative morbidity and mortality,
local control, recurrence patterns, overall survival and
quality of life.
Trial population
This trial focuses on patients with resectable liver
metastases of colorectal cancer. The study includes
patients over 50 years of age. Based on the preoperative
imaging the surgeon determines if the pancreatic tumor
can be resected in curative intent. Patients with unre-
sectable pancreatic cancers, metastasis, secondary malig-
nancies, liver cirrhosis or previous radiotherapy to the
upper abdomen will be excluded from the trial. A
detailed overview of all eligibility and exclusion criteria
is given in Table 1.
Screening/Randomisation/Intervention
Patients will be screened by the Surgery Department
for inclusion criteria. Patients are randomly allocated
to either study intervention to balance treatment
groups for all known and unknown potentially con-
founding factors. A block randomisation list is created
via computer system. The sealed randomisation list is
stored in the principal investigator’s file. Patients are
randomised using consecutively numbered opaque
envelopes prepared and sealed by an independent
study nurse. All patients screened, including those,
w h od i dn o tg i v ei n f o r m e dc o n s e n t ,a r ee n t e r e di na
consecutive list.
Given the consent, patients are randomized either to
the control group - receiving no radiation - or the three
irradiation treatment groups. Within the irradiation
treatment groups patients will receive 0.5 Gy, 2 Gy or 5
Gy single fraction radiation 48 h prior to resection.
After the adjustment of an individual positioning device,
computed tomography and, if needed, magnetic reso-
nance imaging (MRI) treatment planning examinations
are performed. After 3D inverse treatment planning and
plan optimizing using VIRTUOS and KONRAD soft-
ware, intensity modulated radiation therapy will be
administered using five to nine 6 MV (LINAC) photon
beams. Immediately prior to the irradiation the setup
error of the patient will be determined via In-Room-CT,
and corrected if necessary.
Venous blood will be obtained (54 ml) on the day of
radiation treatment planning. A second blood sample
will be obtained just prior to the resection before anaes-
thesia. A bilateral bone marrow sample (each 27 ml)
will be taken after induction of general anaesthesia
immediately before the skin incision after disinfection
from both iliac crests. Bone marrow sampling is optional
for the patient. EDTA and not Heparin will be used as
anticoagulant for bone marrow and blood samples.
After the resection of the tumor a part of the tumor will
be immediately removed and stored at -80°C for further
T cell and other analyses.
On the postoperative day seven and at the follow-up/
restaging visits (4 weeks postoperatively, 4 and 7 months
postoperatively) additional venous blood samples (54
ml) will be obtained. Quality of Life will be tested using
the EORTC QLQ C-30 and the additional PAN-26 at 4
months and 7 months postoperatively. Clinical
Table 1 Eligibility criteria
Inclusion criteria
Resectable pancreatic Carcinoma
Written informed consent of the patient
No evidence of active or former concurrent malignant diseases
Exclusion criteria
Previous radiotherapy to the upper abdomen
Participation in other therapeutical trials
Pregnancy
No willingness on regular follow up care
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be obtained by the investigators at all visits.
Sample size and statistical consideration
Based on the study design, this monocentric randomized
controlled trial is planned as a comparison of four paral-
lel groups.
Group 1: Dose = 0 Gy (control)
Group 2: Dose = 0.5 Gy
Group 3: Dose = 2 Gy
Group 4: Dose = 5 Gy.
Aim of the study is to determine the maximum active
radiation dose with three different doses. This will be
carried out hierarchical, in two consecutive steps.
1. Step: Comparison of the three doses against the
control group ("Many-to-one” comparison after Dunnet)
2. Step: Comparison of the three doses among each
other ("all-subset” comparison) Each of the two steps
happen on multiple level of significance of p < 0.05. The
power of each step should be at least 80%.
Based on advanced information of a study by Galon et
al. in colorectal cancer patients, the density of tumor
infiltrating T cells is a relevant prognostic parameter.
Patients with a good prognosis had a mean of x-good =
600 CD8 T cells/mm
2, the group with the bad prognosis
had a mean of x-bad = 370 CD8 T cells/mm
2. The stan-
dard deviation in both groups was 50/mm
2. Further ana-
l y s i sr e v e a l e dt h a tp a t i e n t sw i t hx=3 0 0t u m o r
infiltrating CD8 T-cells/mm
2 in tumor tissue had a sig-
nificantly improved prognosis. Given this background, a
clinical relevant difference between 100 and 200 CD8 T-
cells/mm
2 seems plausible. The number of cases should
be sufficient for a difference of 150 CD8 T-cells/mm
2.
For the first step n = 32 analyzable patients will be
needed, equals n = 8 for each group. The nominal
power of ANOVA is around 90%. For the second step
(comparison of the best group, Hsu 2006), the power
for n = 32 is 95%. Not all of the randomized patients
will be analyzable with respect to the primary objective.
A failure of 10 - 15% has to be assumed due to bad tis-
sue quality. Therefore n = 40 patients should be
randomized.
The calculated number of cases was carried out with
PASS 2005 (Hintze J, 2004): NCSS and PASS. Number
Cruncher Statistical Systems. Kaysville, Utah. http://
www.ncss.com) with the procedure for multiple compar-
isons by Jason C. Hsu (1996) (Multiple Comparisons:
Theory and methods, Chapman & Hall). The analysis of
the primary objective results confirmatory on a multiple
l e v e lo fs i g n i f i c a n c eo fp<0 . 0 5b yA N O V Ab a s e do n
the calculated number of cases. The analysis of the sec-
ondary objective results is descriptive by determining
the means, the quartiles as location parameter and the
standard deviation and range as dispersion parameters.
The correlation between the parameters will be quanti-
fied by the Pearson or Spearman test.
Study objectives and endpoints
The primary objective of this clinical trial is the amount
of tumor infiltrating T cells, defined by the total number
of CD 8 T cells. Secondary molecular objectives are the
T cell activity in situ, the amount of regulatory T cells
in situ and the frequency of tumor reactive T cells in
blood and bone marrow of the patients. Furthermore,
the study will analyze migration relevant adhesion mole-
cules on tumor related vascular endothelial cells, the
expression of proinflammatory cytokines, and immune-
associated transcription factors in tumor and blood of
the patients. Whole genome wide expression profiling in
whole blood cells will be correlated with clinical out-
come and with immunological response. Additional sec-
ondary clinical objectives are local and systemic
morbidity
All secondary objectives are presented in Table 2.
Follow up
The patients will undergo a routine follow up (physical
examination of the patients, tumor markers (CA 19-9),
CT/MRI) every three months. Disease free survival and
o v e r a l ls u r v i v a lw i l lb er e c o r d e d .T h ec l i n i c a lm a n a g e -
ment and postoperative treatment of the patients will
not be influenced by the results of this study. Decisions
about further adjuvant treatment (e.g. chemotherapy) of
the patients are left to the discretion of the treating
oncologist.
Data management and quality assurance
This trial is coordinated by the Radiation Oncology
Department of the German Cancer Research Center.
The data regarding T cell detection in blood and bone
marrow of all patients will be entered in a password-
protected database at the Department of Surgery, Uni-
versity of Heidelberg and at the German Cancer
Research Center. The clinical data of all included
patients will be centrally collected in a database located
Table 2 Secondary endpoints
￿ Local control and recurrence patterns of pancreatic cancer
￿ Progression free survival
￿ Radiation related toxicity
￿ Surgical morbidity in patients who received this protocol
treatment
￿ 30 day postoperative mortality
￿ Quality of life according to EORTC QoL questionnaire after 3 and
6 months
￿ Plasma proteomics
￿ Whole blood transcriptomics
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clinical and laboratory data will be merged in the pass-
word-protected database at the Department of Surgery,
University of Heidelberg, Germany and at the German
Cancer Research Center.
Current status
At the current time of writing we have randomized 17
patients. The duration of the trial is expected to last 9
more months. A scheduled interims analysis will be per-
formed following the inclusion of the first 20 patients.
Evaluation and reporting of the clinical and laboratory
results will be done within 3 months of the end of
recruitment and closing of the database.
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